Central and Peripheral Adiposity and Iron Absorption
Not Applicable
Completed
- Conditions
- Iron-deficiencyAdiposity
- Interventions
- Other: Stable iron isotopes
- Registration Number
- NCT03642223
- Lead Sponsor
- Swiss Federal Institute of Technology
- Brief Summary
Adiposity is a state of sub-clinical inflammation, thus hepcidin is increased in adiposity, often leading to iron deficiency in this population group. Central adiposity is generally considered having a greater negative effect on health compared to peripheral adiposity. Whether this can be also seen in hepcidin and thereby in iron absorption is uncertain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 121
Inclusion Criteria
- either normal-weight (BMI 18-25kg/m2) or overweight/obese (BMI 28-50kg/m2) with either central or peripheral fat deposits based on DEXA
Exclusion Criteria
- Iron Supplement or antibiotic intake within 2 weeks before study start
- diagnosed chronic disease or gastrointestinal disorders
- regular use of medication (except contraceptives)
- pregnancy
- lactation
- smoking
- blood donation or surgery within the last 4 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description central adiposity Stable iron isotopes - peripheral adiposity Stable iron isotopes - normal-weight Stable iron isotopes -
- Primary Outcome Measures
Name Time Method Fractional and total iron absorption 14days after the administration of the test meal
- Secondary Outcome Measures
Name Time Method Serum IL-6 at baseline inflammation status
Serum AGP at baseline inflammation status
Serum Hepcidin at baseline Serum ferritin at baseline iron status
Serum TfR at baseline iron status
Serum CRP at baseline inflammation status
Trial Locations
- Locations (1)
American University of Beirut
🇱🇧Beirut, Lebanon